Phase I trial of interleukin-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia

CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONOR,S

1974 • 3,686 citations

Graft-versus-leukemia reactions after bone marrow transplantation

1990 • 2,781 citations

Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts

1979 • 1,538 citations

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.

1995 • 1,320 citations

Bone Marrow Transplantation for Chronic Myelogenous Leukemia in Chronic Phase

1988 • 887 citations

T-cell depletion of HLA-identical transplants in leukemia

1991 • 771 citations

Cytokine dysregulation and acute graft-versus-host disease

1992 • 617 citations

Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens [see comments]

1990 • 525 citations

Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts

1985 • 517 citations

Immune reconstitution following bone marrow transplantation: comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts

1989 • 261 citations

Graft-versus-leukemia: no longer an epiphenomenon [editorial]

1993 • 197 citations

Host-Specific Interleukin-2–Secreting Donor T-Cell Precursors as Predictors of Acute Graft-versus-Host Disease in Bone Marrow Transplantation between HLA-Identical Siblings

1992 • 167 citations

Effect of low-dose interleukin-2 on disease relapse after T-cell- depleted allogeneic bone marrow transplantation

1994 • 152 citations

Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation.

1988 • 138 citations

Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy

1989 • 130 citations

Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells.

1990 • 122 citations

Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies

1991 • 118 citations

Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia

1994 • 114 citations

Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation

1990 • 112 citations

Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia.

1993 • 101 citations

High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse

1991 • 95 citations

Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy

1989 • 93 citations

Impact of donor and recipient characteristics on the development of acute and chronic graft-versus-host disease following pediatric bone marrow transplantation.

1995 • 93 citations

Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects

1994 • 93 citations

A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease

1989 • 89 citations

Marrow transplantation for children in first remission of acute nonlymphoblastic leukemia: an update

1985 • 79 citations

Use of Recombinant Human Interleukin-2 in Conjunction with Bone Marrow Transplantation as a Model for Control of Minimal Residual Disease in Malignant Hematological Disorders: I. Treatment of Murine Leukemia in Conjunction with Allogeneic Bone Marrow Transplantation and IL-2-Activated Cell-Mediated Immunotherapy

1992 • 77 citations

Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells.

1989 • 72 citations

Marrow transplant experience in children with acute lymphoblastic leukemia: An analysis of factors associated with survival, relapse, and graft‐versus‐host disease

1985 • 72 citations

T-cell depletion of allogeneic bone marrow prevents acceleration of graft-versus-host disease induced by exogenous interleukin 2

1986 • 52 citations

Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies.

1989 • 48 citations

Immunotherapy with interleukin 2 after ABMT in AML.

1993 • 47 citations

Graft-versus-host disease in children: the AIEOP-BMT Group experience with cyclosporin A.

1993 • 44 citations

Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantation.

1989 • 44 citations

Induction and Persistence of Complete Remission in a Resistant Acute Myeloid Leukemia Patient after Treatment with Recombinant Interleukin-2

1990 • 42 citations

Are new conditioning regimens for transplants in acute myelogenous leukemia better?

1991 • 38 citations

Interleukin-2 therapy after autologous bone marrow transplantation for hematologic malignancies.

1993 • 25 citations

Interleukin-2 in therapy of hematologic malignancies [editorial; comment]

1994 • 22 citations

Therapy of advanced acute myeloblastic leukemia with cytarabine and interleukin 2

1991 • 7 citations